Skip to main content
Top
Published in:

01-05-2020 | Lung Cancer | Case report

Gefitinib/osimertinib

Acquired drug resistance and transformation to small cell lung cancer: case report

Published in: Reactions Weekly | Issue 1/2020

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Ma S, et al. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- And third-generation EGFR-TKIs: A case report. Translational Lung Cancer Research 9: 139-143, No. 1, Feb 2020. Available from: URL: http://doi.org/10.21037/tlcr.2020.01.07 Ma S, et al. Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- And third-generation EGFR-TKIs: A case report. Translational Lung Cancer Research 9: 139-143, No. 1, Feb 2020. Available from: URL: http://​doi.​org/​10.​21037/​tlcr.​2020.​01.​07
Metadata
Title
Gefitinib/osimertinib
Acquired drug resistance and transformation to small cell lung cancer: case report
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2020
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-78563-y